SCHEMBL4864904

SCHEMBL4864904

NC(c1ccccn1)c1nc(N2CCOCC2)nc2occ(-c3ccccc3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK4 Q13043 1/20 0.38
STK3 Q13188 1/20 0.38
LRRK2 Q5S007 1/20 0.38
LMNA P02545 5/20 0.38
ALDH1A1 P00352 4/20 0.38
PIK3CA P42336 7/20 0.37
MTOR P42345 6/20 0.37
PIK3R1 P27986 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TSHR P16473 2/20 0.37
MAPT P10636 1/20 0.37
HSD17B10 Q99714 3/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368516 0.82 LMNA (0.50) LMNANPSR1TSHRMAPTHTT
SCHEMBL3387494 0.76 HTT (0.44) STK4STK3LRRK2LMNAALDH1A1
SCHEMBL4865898 0.76 PTGS2 (0.33) LMNAALDH1A1NPSR1MAPTHSD17B10
SCHEMBL4862839 0.73 KDR (0.32)
SCHEMBL4864910 0.73 PIK3CA (0.52) ALDH1A1PIK3CAHTTKDM4EPIK3CB
SCHEMBL3387613 0.71 KDM4E (0.48) LRRK2LMNANPSR1MAPTKDM4E
SCHEMBL2368668 0.69 LMNA (0.55) LMNAALDH1A1NPSR1TSHRMAPT
SCHEMBL3383761 0.67 LMNA (0.55) LMNAALDH1A1NPSR1TSHRMAPT
SCHEMBL13761287 0.63 HTT (0.61) LMNAALDH1A1PIK3CAMTORPIK3R1
SCHEMBL28374591 0.62 KCNA5 (0.50) LMNAALDH1A1TSHRHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US claimed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US claimed
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US disclosed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP disclosed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO disclosed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors KCNH3, HCN4, KCNH2 STK4 1467/4885STK3 2359/4885LRRK2 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.